Why Biogen Isn't a Buy After Its Alzheimer's Drug Approval
Biogen (NASDAQ: BIIB) has been a huge winner for investors who owned the stock in anticipation of U.S. Food and Drug Administration (FDA) approval of its Alzheimer's disease drug, Aduhelm. In this Motley Fool Live video recorded on June 9, Motley Fool contributors Keith Speights and Brian Orelli discuss one reason why Biogen isn't a buy after its key FDA victory.